David Gill Biography and Net Worth

Director of Evolus

David Gill has served as a member of our board of directors since February 2018. Mr. Gill has over 30 years’ experience in the medical device and life sciences industries and most recently served as the Chief Financial Officer of Perspectum, Ltd, a healthcare technology company which transforms the clinical management of metabolic disease and cancer. Mr. Gill also currently serves as a director of Y-mAbs Therapeutics, Inc. as well as several private companies. Previously he served on the board of directors of Strongbridge Biopharma, PLC from September 2019 to October 2021, Histogenics, Inc. from January 2015 to July 2019, Melinta Therapeutics, Inc (f/k/a Cempra Inc. from April 2012 to April 2020, and Strata Skin Sciences from May 2018 to May 2020. Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several publicly-traded companies, including EndoChoice, Inc., NxStage Medical, Inc., CTI Molecular Imaging, Inc., Interland Inc. and Novoste Corporation. Mr. Gill holds a B.S. in Accounting from Wake Forest University and an M.B.A. from Emory University, and is a certified public accountant (inactive).

What is David N. Gill's net worth?: The estimated net worth of David N. Gill is at least $277.04 thousand as of May 13th, 2024. Gill owns 40,682 shares of Evolus stock worth more than $277,044 as of December 5th. This net worth evaluation does not reflect any other investments that Gill may own. Learn More about David N. Gill's net worth.
How do I contact David N. Gill?: The corporate mailing address for Gill and other Evolus executives is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. Evolus can also be reached via phone at (949) 284-4555 and via email at [email protected]. Learn More on David N. Gill's contact information.
Has David N. Gill been buying or selling shares of Evolus?: David N. Gill has not been actively trading shares of Evolus over the course of the past ninety days. Most recently, David N. Gill sold 3,643 shares of the business's stock in a transaction on Monday, May 13th. The shares were sold at an average price of $12.72, for a transaction totalling $46,338.96. Following the completion of the sale, the director now directly owns 40,682 shares of the company's stock, valued at $517,475.04. Learn More on David N. Gill's trading history.
Who are Evolus' active insiders?: Evolus' insider roster includes Rui Avelar (Insider), David Gill (Director), David Gill (Director), Vikram Malik (Director), David Moatazedi (Insider), Albert White, III (Director), and Tomoko Yamagishi-Dressler (CMO). Learn More on Evolus' active insiders.
Are insiders buying or selling shares of Evolus?: During the last twelve months, Evolus insiders bought shares 2 times. They purchased a total of 50,000 shares worth more than $393,600.00. During the last twelve months, insiders at the sold shares 13 times. They sold a total of 223,706 shares worth more than $2,416,073.05. The most recent insider tranaction occured on August, 22nd when CMO Tomoko Yamagishi-Dressler sold 5,722 shares worth more than $42,972.22. Insiders at Evolus own 5.9% of the company. Learn More about insider trades at Evolus.
Information on this page was last updated on 8/22/2025.

David N. Gill Insider Trading History at Evolus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/13/2024	Sell	3,643	$12.72	$46,338.96	40,682
5/16/2022	Sell	5,000	$13.62	$68,100.00	29,568
5/13/2022	Sell	5,313	$13.10	$69,600.30	34,568
6/13/2019	Buy	2,000	$13.65	$27,300.00
12/14/2018	Buy	3,000	$12.77	$38,310.00

David N. Gill Buying and Selling Activity at Evolus

Evolus Company Overview

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Today's Range

Now: $6.81

$6.69

$6.85

50 Day Range

MA: $6.67

$5.99

$7.37

2 Week Range

Now: $6.81

$5.71

$17.12

Volume

541,556 shs

Average Volume

1,639,299 shs

Market Capitalization

$441.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87